Navigation Links
Intralytix, Inc. and BioPhage Therapeutics Limited Partner to Develop Topical Bacteriophage Treatments of Human Wounds Infected With S. Aureus
Date:4/5/2017

BALTIMORE, April 4, 2017 /PRNewswire/ -- Intralytix, Inc. announced today that the Company is partnering with BioPhage Therapeutics Limited to develop and commercialize topical bacteriophage treatments of human wounds infected or colonized with S. aureus.

"Treatment of bacteria-infected wounds is one the most critical problems in modern medicine. Infected wounds complicate healing, often necessitate repeated surgical interventions, and may lead to amputation of extremities or even death.  The problem is compounded by the increasing emergence of multi-antibiotic-resistant bacteria – such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) - that may colonize the wounds and make their successful treatment very difficult or even impossible to achieve," stated Dr. Alexander Sulakvelidze, Intralytix's Chief Scientist.  "The ultimate goal of our partnership with BioPhage is to develop and make commercially available a novel phage-based topical treatment approach for managing wounds infected with S. aureus, including wounds infected with multidrug-resistant or pan-resistant strains (i.e., strains resistant to all major classes of antibiotics)," Dr. Sulakvelidze added.

"We view this partnership as an important step in developing phage-based products for managing wounds infected with S. aureus," stated John Woloszyn, Intralytix's CEO.  "Working with BioPhage Therapeutics, we aim to rapidly bring our bacteriophage technology to the market, and to offer a natural, safe, and effective antimicrobial approach to millions of people suffering from infected, hard-to-heal wounds," Mr. Woloszyn added.

Intralytix, Inc. is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety, animal health, human therapeutics, and dietary supplements and probiotics.  The Company has the world's largest portfolio of FDA-approved phage preparations for food safety applications and is involved in the development of several additional products for human therapeutic, veterinary medicine, probiotic, and other applications.

BioPhage Therapeutics Limited is a British company with strong skills in the clinical development, registration, and marketing of therapeutic drug products.  "The partnership with Intralytix is ideal," stated Robert Jackson, Chairman of BioPhage.  "We can build upon Intralytix's strength in bacteriophage science by formulating their phage into a drug product that will be in clinical trials at leading UK teaching hospitals by the end of the year."

For more information, contact: 

At Intralytix: Mr. John Woloszyn (410-625-3813 or jwoloszyn@intralytix.com) or Dr. Alexander Sulakvelidze (410-625-2533 or asulakvelidze@intralytix.com).

At BioPhage: Mr. Robert Jackson (+44-7785-318254 or robertwardjackson@msn.com) or Mr. Tim Butler (+44-7711-421944 or timbutler5@gmail.com).

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intralytix-inc-and-biophage-therapeutics-limited-partner-to-develop-topical-bacteriophage-treatments-of-human-wounds-infected-with-s-aureus-300434608.html


'/>"/>
SOURCE Intralytix, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Sorrento Therapeutics anti-CEA CAR-T Demonstrates Promising Clinical Activity and Safety in Phase Ib Clinical Trial
2. Biotech Stocks Under Scanner -- Rexahn Pharma, Northwest Biotherapeutics, Celldex Therapeutics, and Vertex Pharma
3. Spiral Therapeutics Acquires an Exclusive Option to Develop Two Neuroprotective Agents for the Treatment of Inner Ear Disorders
4. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
5. Akcea Therapeutics Announces Three Additions to Board of Directors
6. Milner Therapeutics Institute Announces New Partnership with Elysium Health
7. ImMAGE Biotherapeutics DNA immunotherapy shows high efficacy with low toxicology results
8. Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center
9. Healthcare Stocks on Investors Radar -- Depomed, Novartis AG, TherapeuticsMD, and Tonix Pharma
10. Pain Therapeutics Attendee List Released Featuring Scientific Leaders and Top Industry Experts
11. PTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2019)... ... 13, 2019 , ... The Allergenic Products Advisory Committee of the Food and ... data, to recommend approval of a standardized oral immunotherapy (OIT) product for peanut allergy. ... as AR101. , The FDA would require a Risk Evaluation and Mitigation Strategy (REMS) ...
(Date:9/14/2019)... ... September 14, 2019 , ... ... plaintiffs living with peritoneal mesothelioma, a jury in Middlesex County found Johnson & ... of plaintiffs alleging their mesotheliomas were caused by asbestos-containing J&J talc products. ...
(Date:9/12/2019)... ... September 12, 2019 , ... ... help make the services of CPESN’s clinically integrated network of more than 2,400 ... CPESN USA’s participating pharmacies provide high quality clinical service programs that will now ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... September 17, 2019 , ... Caravan Health ... organization (ACO) in the country, the company announced today. High-performing community health systems ... quality and increase cost efficiency. This opportunity is open to those new to ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:9/17/2019)... (PRWEB) , ... September 17, ... ... host the October 18 "Pacifica Experience" Open House day on Pacifica's Lambert ... doctoral degree programs in Depth Psychology, the Humanities, Clinical Psychology, Counseling Psychology, ...
(Date:9/11/2019)... (PRWEB) , ... September 12, 2019 , ... “Heart Seizures”: ... with diagnosed coronary artery disease as he hopes to prevent anyone from having it ... of published author John Saltwick, a writer who was diagnosed with coronary artery disease. ...
(Date:9/11/2019)... ... 11, 2019 , ... The 2019 Minnesota Anatomic Complex Knee ... Mall of America Radisson Blu. Four experts from Twin Cities Orthopedics (TCO), including ... conference, which brings together more than 100 national and international orthopedic surgeons for ...
Breaking Medicine News(10 mins):